


***EVI1* overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-*AF9* rearranged acute myeloid leukemia**

Hidemasa Matsuo,<sup>1</sup> Mio Kajihara,<sup>1</sup> Daisuke Tomizawa,<sup>2</sup> Tomoyuki Watanabe,<sup>3</sup> Akiko Moriya Saito,<sup>4</sup> Junichiro Fujimoto,<sup>5</sup> Keizo Horibe,<sup>4</sup> Kumi Kodama,<sup>1</sup> Mayu Tokumasu,<sup>6</sup> Hiroshi Itoh,<sup>1</sup> Hideki Nakayama,<sup>7</sup> Akitoshi Kinoshita,<sup>8</sup> Takashi Taga,<sup>9</sup> Akio Tawa,<sup>10</sup> Tomohiko Taki,<sup>11</sup> Norio Shiba,<sup>12</sup> Kentaro Ohki,<sup>13</sup> Yasuhide Hayashi,<sup>13</sup> Yuka Yamashita,<sup>14</sup> Akira Shimada,<sup>15</sup> Shiro Tanaka,<sup>16</sup> and Souichi Adachi<sup>1</sup>

<sup>1</sup>Department of Human Health Sciences, Kyoto University; <sup>2</sup>Department of Pediatrics, Tokyo Medical and Dental University (TMDU); <sup>3</sup>Department of Nutritional Science, Aichi Gakuin University, Nisshin; <sup>4</sup>Clinical Research Center, National Hospital Organization Nagoya Medical Center; <sup>5</sup>Epidemiology and Clinical Research Center for Children's Cancer, National Center for Child Health and Development, Tokyo; <sup>6</sup>Department of Pediatrics, Kyoto University; <sup>7</sup>Department of Pediatrics, National Hospital Organization Fukuoka-Higashi Medical Center, Koga; <sup>8</sup>Department of Pediatrics, St. Marianna University School of Medicine, Kawasaki; <sup>9</sup>Department of Pediatrics, Shiga University of Medical Science, Otsu; <sup>10</sup>Department of Pediatrics, National Hospital Organization Osaka National Hospital; <sup>11</sup>Department of Molecular Diagnostics and Therapeutics, Kyoto Prefectural University of Medicine; <sup>12</sup>Department of Pediatrics, Gunma University Graduate School of Medicine, Maebashi; <sup>13</sup>Department of Hematology and Oncology, Gunma Children's Medical Center, Shibukawa; <sup>14</sup>Department of Pediatrics, National Hospital Organization Nagoya Medical Center; <sup>15</sup>Department of Pediatrics, Okayama University Hospital; and <sup>16</sup>Department of Pharmacoepidemiology, Kyoto University, Japan

Correspondence: [adachiso@kuhp.kyoto-u.ac.jp](mailto:adachiso@kuhp.kyoto-u.ac.jp)  
doi:10.3324/haematol.2014.107128

Supplementary Figure S1. *EVI1* expression in different *MLL* translocation partners.



## Supplementary Table S1.

### Multivariate analysis of high *EVII* expression as prognostic factor for survival.

	EFS			OS		
	HR	95% CI	P value	HR	95% CI	P value
<b>Multivariate analysis in all patients (n=50)</b>						
<i>EVII</i> <sup>+</sup>	4.94	1.89-12.88	<0.01	1.80	0.54-5.97	0.34
<i>FLT3</i> -ITD	0.58	0.12-2.70	0.49	2.29	0.42-12.50	0.34
Age (+1 year)	1.03	0.93-1.13	0.59	1.02	0.90-1.15	0.73
WBC (>50000)	1.32	0.57-3.07	0.52	2.13	0.69-6.57	0.19
<b>Multivariate analysis in <i>MLL-AF9</i> patients (n=29)</b>						
<i>EVII</i> <sup>+</sup>	33.81	3.74-305.78	<0.01	7.37	0.72-75.53	0.09
<i>FLT3</i> -ITD	0.50	0.09-2.87	0.43	2.29	0.29-17.86	0.43
Age (+1 year)	1.11	0.93-1.32	0.23	1.14	0.93-1.39	0.21
WBC (>50000)	1.58	0.40-6.28	0.51	3.74	0.51-27.65	0.20

*EFS*: event-free survival; *OS*: overall survival; *HR*: hazard ratio; *CI*: confidence interval; *WBC*: white blood cell count.